Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert A Beckman

Showing results (1-10 of 81) with videos related to

Pageof 9
Sort By:
Plos One|June 12, 2009
Mutator mutations enhance tumorigenic efficiency across fitness landscapesRobert A Beckman
NPJ Systems Biology and Applications|October 2, 2024
Neutral evolution of rare cancer mutations in the computer and the clinicRobert A Beckman
Seminars in Cancer Biology|October 12, 2010
Efficiency of carcinogenesis: is the mutator phenotype inevitable?Robert A Beckman
Biotechniques|October 21, 2005
Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody developmentLi Yan, Robert A Beckman
Chinese Journal of Cancer|March 16, 2013
New evidence-based adaptive clinical trial methods for optimally integrating predictive biomarkers into oncology clinical development programsRobert A Beckman, Cong Chen
Journal of Biopharmaceutical Statistics|April 23, 2009
Optimal cost-effective designs of Phase II proof of concept trials and associated go-no go decisionsCong Chen, Robert A Beckman
Advances in Experimental Medicine and Biology|November 5, 2015
Efficient, Adaptive Clinical Validation of Predictive Biomarkers in Cancer Therapeutic DevelopmentRobert A Beckman, Cong Chen
Biomarkers in Medicine|September 3, 2015
Translating predictive biomarkers within oncology clinical development programsRobert A Beckman, Cong Chen
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2014
Maximizing return on socioeconomic investment in phase II proof-of-concept trialsCong Chen, Robert A Beckman
Biology Direct|October 25, 2016
Long range personalized cancer treatment strategies incorporating evolutionary dynamicsChen-Hsiang Yeang, Robert A Beckman
Pageof 9

Showing results (1-10 of 81) with videos related to

Sort By:
Pageof 9
Plos One|June 12, 2009
Mutator mutations enhance tumorigenic efficiency across fitness landscapesRobert A Beckman
NPJ Systems Biology and Applications|October 2, 2024
Neutral evolution of rare cancer mutations in the computer and the clinicRobert A Beckman
Seminars in Cancer Biology|October 12, 2010
Efficiency of carcinogenesis: is the mutator phenotype inevitable?Robert A Beckman
Biotechniques|October 21, 2005
Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody developmentLi Yan, Robert A Beckman
Chinese Journal of Cancer|March 16, 2013
New evidence-based adaptive clinical trial methods for optimally integrating predictive biomarkers into oncology clinical development programsRobert A Beckman, Cong Chen
Journal of Biopharmaceutical Statistics|April 23, 2009
Optimal cost-effective designs of Phase II proof of concept trials and associated go-no go decisionsCong Chen, Robert A Beckman
Advances in Experimental Medicine and Biology|November 5, 2015
Efficient, Adaptive Clinical Validation of Predictive Biomarkers in Cancer Therapeutic DevelopmentRobert A Beckman, Cong Chen
Biomarkers in Medicine|September 3, 2015
Translating predictive biomarkers within oncology clinical development programsRobert A Beckman, Cong Chen
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2014
Maximizing return on socioeconomic investment in phase II proof-of-concept trialsCong Chen, Robert A Beckman
Biology Direct|October 25, 2016
Long range personalized cancer treatment strategies incorporating evolutionary dynamicsChen-Hsiang Yeang, Robert A Beckman
Pageof 9